UKB-PRISM will apply Alamar's NULISA ultrasensitive proteomics platform to 80,000 archived UK Biobank blood samples, measuring hundreds of low-abundance circulating proteins linked to Alzheimer's, Parkinson's and rare dementias. Because the samples were drawn years to decades before diagnosis, the design tests whether neurodegeneration leaves a detectable blood signature during the asymptomatic phase. Results are expected by the end of 2027, with data released on open access terms.
Key Points
- 80,000 pre-diagnosis UK Biobank samples screened for low-abundance brain proteins
- Ultrasensitive assay targets signals years before dementia or Parkinson's symptoms
- Cohort skews healthier, wealthier, less diverse; findings require broader validation
Longevity Analysis
Neurodegeneration begins long before cognition declines, and the window where intervention plausibly matters sits entirely within that silent interval. Measuring proteins involved in tissue repair and inflammatory regulation in people who were still well shifts brain health from a diagnosis made after loss to a trajectory that can be read and acted upon — the difference between reacting to damage and addressing the conditions that permit it. The caution is proportionate: an association between a circulating protein and later illness is not yet a clinical test, and a cohort healthier than the general population limits how far the signal travels.
Original published by Longevity.Technology, by Eleanor Garth.